期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

类风湿关节炎的常见药物基因组学研究进展 被引量：2

原文传递
导出
摘要 药物基因组学是药理学和遗传学的交叉学科，它通过研究基因结构多态性与不同药物反应之间的关系，解释由于个体之间的差异所表现出药物的不同治疗效果或者不良反应的发生，从而为患者或特定人群寻找“疗效肯定、不良反应小”的药物。最新研究显示，药物代谢的某些基因与疾病表型也存在一定的关系，因而药物基因组学研究具有重要的理论意义和广阔的应用前景。
作者 李芬 陈进伟 高洁生 卢放根
机构地区 中南大学湘雅二医院风湿免疫科 中南大学湘雅二医院消化科
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2012年第12期841-844,共4页 Chinese Journal of Rheumatology
基金 基金项目：国家自然科学基金面上项目（81172850）
关键词 药物基因组学 类风湿关节炎 不良反应 治疗效果 结构多态性 交叉学科 药物反应 疾病表型
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献22

  • 1Davis LA, Cannon GW, Pointer LM, et al. Methotrexate use,MTHFR polymorphisms and traditional risk factors in predictingcardiovascular events in elderly males with rheumatoid arthritis(RA). Ann Rheum Dis, 2011, 70: 92-93.
  • 2Wessels JAM, van der Kooij SM, Cessie SL, et al. A clinicalpharmacogenetic model to predict the efficacy of methotrexatemonotherapy in recent-onset rheumatoid arthritis. ArthritisRheum, 2007 , 56: 1765-1775.
  • 3Fisher MC, Cronstein BN. Meta-analysis of methylenetetrahydrofo-late reductase (MTHFR) polymorphisms affecting methotrexatetoxicity. J Rheumatol, 2009, 36: 539-545.
  • 4肖会,徐建华,周小妹,张志华,申世华,李迎伟.类风湿关节炎患者亚甲基四氢叶酸还原酶基因多态性与甲氨蝶呤治疗的相关性研究[J].安徽医科大学学报,2011,46(11):1157-1161. 被引量：2
  • 5Hayashi H, Fujimaki C, Daimon T, et al. Genetic polymor-phisms in folate pathway enzymes as a possible marker for pre-dicting the outcome of methotrexate therapy in Japanese patientswith rheumatoid arthritis. J Clin Pharm Ther, 2009, 34: 355-361.
  • 6Straaten RJ, Wessels JA, Vries-Bouwstra JK, et al. Exploratoryanalysis of four polymorphisms in human GGH and FPGS genesand their effect in methotrexate-treated rheumatoid arthritis pa-tients. Phannacogenomics, 2007, 8: 141-150.
  • 7Chen J, Chen L,Mao N, et al. Association of the MDR1 3435polymorphism in patients with refractory rheumatoid arthritis in aChinese population. Rheumatol Int, 2012,32: 3127-3130.
  • 8Mikuls TR, Levan T, Gould KA, et al. Impact of interactions ofcigarette smoking with NAT2 polymorphisms on rheumatoidarthritis risk in African Americans. Arthritis Rheum, 2012,64:655-664.
  • 9Taniguchi A, Urano W, Tanaka E,et al. Validation of the asso-ciations between single nucleotide polymorphisms or haplotypesand responses to disease-modifying antirheumatic drugs in pa-tients with rfieumatoid arthritis: a proposal for prospective phar-macogenomic study in clinical practice. Pharmacogenet Ge-nomics, 2007, 17: 383-390.
  • 10Behrens F, Koehm M,Burkhardt H. Update 2011: leflunomidein rheumatoid arthritis: strengths and weaknesses. Curr OpinRheumatol? 2011, 23: 282-287.

二级参考文献41

  • 1Jones G, Halbert J, Crotty M, et al. The effect of treatment on ra- diological progression in rheumatoid arthritis : a systematic review of randomized placebocontrolled trials [ J ]. Rheumatology ( Oxford ),2003,42( 1 ) :6 - 13.
  • 2Wessels J A,de Vries-Bonwstro J K,Heijmans B T,et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associ- ated with single-nucleotide polymorphisms in genes coding for fo- late parthway enzymes [ J ]. Arthritis Rheum, 2006,54 ( 4 ) : 1087 -95.
  • 3Weisman M H, Furst D E, Park G S, et al. Risk genotype in folate- dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis [ J ]. Arthritis Rheum ,2006,54 (2) :607 - 12.
  • 4Ogino S, Wilson R B. Genotype and haplotype distributions of MTHFR 677C > T and 1298A > C single nucleotide polymor- phisms : a meta-analysis [ J ]. J Hum Genet,2003,48 ( 1 ) : 1 - 7.
  • 5Kim S K,Jun J B, El-Sonemy A, et al. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate [J]. J Rheumatol,2006,33(7) :1266 -74.
  • 6Urano W,Taniguchi A, Yamanaka H, et al. Potymorphisms in the methylenetetrahydrofolate reductase gene were associated with the efficacy and the toxicity of mcthotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus methylenetetra- hydrofolate reductase gene and haplotype analyses [ J ]. Pharmaco- genetics ,2002,12 ( 3 ) : 181 - 2.
  • 7Fisher M C,Cronstein B N. Meta-analysis of methylenetetrahydro- folate reductase ( MTHFR ) polymorphisms affecting methotrexate toxicity [ J ]. J Rheumatol,2009,36 ( 3 ) : 539 - 45.
  • 8Hughes L B, Beasley T M, Patel H, et al. Racial or ethnic differ- ences in allele frequencies of single - nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis[ J]. Ann Rheum Dis,2006,65 (9) :1213 -8.
  • 9Kumagaik K, Hiyama K, Oyama T, et al. Polymorphisms in the thy- midylate synthase and MTHFR genes and sensitivity to the low- dose methotrexate therapy in patients with rheumatoid arthritis[ J ]. Int J Mol Med,2003,11 ( 5 ) : 593 - 600.
  • 10Taraborelli M, Andreoli L, Archetti S, et al. Methylenetetrahydrofo- late reductase polymorphisms and methotrexate:no association with response to therapy nor with drug-related adverse events in an Ital- ian population of rheumatic patients [ J ]. Clin Exp Rheumatol, 2009,27 ( 2 ) :499 - 502.

共引文献7

同被引文献48

  • 1Van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue[J]. Ann Rheum Dis, 2007, 66 : 849-851.
  • 2Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis[J]. Ann Rheum Dis, 2009, 68: 1739-1745.
  • 3Miossec P, Verweij CL, Klareskog L, et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies[J]. Ann Rheum Dis, 2011, 70: 1713-1718.
  • 4Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor-c (TNF-ct) promoter -308 G/A and response to TNF-ct blockers in rheumatoid arthritis: a meta-analysis[J]. Mod Rheumatol, 2013, 23: 489-45.
  • 5Kang CP, Lee KW, Yoo DI, et al. The influence of a poly- morphism at position -857 of e tumour necrosis factor gene on clinical response to etanercept therapy in rheumatoid arthritis[J]. Rheumatology, 2005, 44: 547-552.
  • 6Miceli RC, Comets E, Verstuyft C, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis[J]. Ann Rheum Dis, 2008, 67: 478-484.
  • 7Pavy S, Toonen E J, Miceli RC, et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response t TNF alpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis[J]. Ann Rheum 010, 69: 1022-1028.
  • 8Ongaro A, de Mattei M, Pellati A, et al. Can tumor necrosis factor receptor lI gene 676T >G polymorphism predict the re- sponse grading to anti-TNF ilpha therapy in rheumatoid arthritis? [J]. Rheumatol Int, 2008, 28: 901-908.
  • 9Criswell LA, Lum RF, Turner KN, et al. The influence of" genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with metho- trexate or etanercept[J]. Arthritis Rheum, 2004, 50: 2750-2756.
  • 10Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumor necrosis factor response in rheumatoid arthritis[J]. Ann Rheum Dis, 2009, 68: 69-74.

引证文献2

二级引证文献11

中华风湿病学杂志
2012年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部